The clinical benefits are modest at best, with uncertain impacts on quality of life
Canada has opened a door that many Alzheimer's patients and families have long hoped for, yet the threshold is complicated: lecanemab can slow the disease's march, but only modestly, and at a cost — financial, physical, and emotional — that demands careful reckoning. The approval of this amyloid-clearing drug reflects medicine's enduring struggle to match the urgency of human suffering with the humility of incomplete evidence. In a country that prizes universal care, the drug's $35,000–$40,000 annual price tag, largely uninsured, quietly redraws the line between hope and access.
- Canada's approval of lecanemab arrives not as a breakthrough but as a carefully hedged permission — the drug slows early Alzheimer's, but the clinical gains are modest and their meaning for daily life remains genuinely uncertain.
- The treatment is burdensome by design: patients must confirm amyloid buildup through PET scans or spinal taps, then commit to regular IV infusions and frequent MRI monitoring for brain swelling and small bleeds.
- At $35,000–$40,000 per year with most provinces yet to commit to public coverage, the drug risks becoming a privilege of wealth inside a system built on the premise that care should not be.
- Clinicians are being asked to hold the tension — neither pushing patients toward a drug with real risks nor dismissing the value that even a modest delay in decline can hold for those living inside the disease.
- Medical experts are landing on shared decision-making as the responsible path forward, with waiting for stronger evidence named explicitly as a legitimate and reasonable choice.
Canada has approved lecanemab for early Alzheimer's disease, but the decision comes weighted with caveats. Writing in the Canadian Medical Association Journal, geriatrician Dr. Sharon Straus and colleagues at Unity Health Toronto offer a measured assessment: the drug's clinical benefits are modest, its effects on quality of life and caregiver burden remain uncertain, and the risks it carries are real.
Lecanemab works by clearing amyloid, the protein that accumulates in Alzheimer's-affected brains. But dissolving amyloid does not automatically produce the meaningful improvements patients and families hope for. The treatment is also demanding — eligibility requires confirmed amyloid buildup via PET scan or lumbar puncture, followed by regular intravenous infusions and frequent MRI monitoring for complications including brain swelling and small bleeds. For some, these risks will be manageable; for others, they may tip the balance against treatment.
The financial dimension adds another layer of difficulty. At $35,000–$40,000 annually, and with most provinces yet to commit to public coverage, the drug creates a quiet rationing by wealth — a tension that sits uneasily within Canada's universal health care framework.
Straus and her coauthors recommend structured shared decision-making between clinicians, patients, and caregivers. They acknowledge that some people — particularly those who place high value on even a small delay in decline — may find the trade-offs worthwhile. But they are equally clear that choosing to wait for stronger evidence is a reasonable path. Approval, they suggest, does not answer whether any individual should take the drug. It simply makes the question possible to ask — with full awareness of both what the drug offers and what it costs.
Canada has approved lecanemab for early Alzheimer's disease, but the decision arrives with a complicated asterisk: the drug's benefits are modest at best, it carries genuine risks of serious harm, and it costs between $35,000 and $40,000 per year—a price tag that patients must largely cover themselves, since most provinces have not committed to public funding.
The approval reflects a broader tension in modern medicine: the hunger for any tool that might slow cognitive decline in a disease that devastates individuals and families, weighed against the actual evidence of what this particular tool can do. In an analysis published in the Canadian Medical Association Journal, Dr. Sharon Straus, a geriatrician at Unity Health Toronto, and her colleagues lay out the calculus with careful precision. The clinical benefits, they write, are modest. The impacts on quality of life, independence, and the burden on caregivers remain uncertain. The drug works by clearing amyloid, a protein that accumulates in the brains of people with Alzheimer's, but clearing that protein does not automatically translate into the kind of meaningful improvement patients and their families hope for.
The treatment itself is demanding. Eligible patients must have early Alzheimer's disease and confirmed amyloid buildup in the brain—a diagnosis that requires either a PET scan or a lumbar puncture with cerebrospinal fluid analysis. Once enrolled, they receive regular intravenous infusions and undergo frequent MRI scans to monitor for complications. Those complications are not trivial: brain swelling and small brain bleeds can occur as the drug works to dissolve the amyloid plaques. For some patients, these adverse effects will be manageable. For others, they may outweigh any benefit.
The financial barrier is substantial. At $35,000 to $40,000 annually, lecanemab is expensive by any standard. In Canada's publicly funded health system, this matters enormously. Most provinces and territories have not yet decided whether they will cover the cost through provincial insurance plans, leaving patients to navigate the decision largely on their own dime. This creates a de facto rationing by ability to pay—a reality that sits uneasily in a country with universal health care.
Straus and her coauthors recommend that clinicians engage in shared decision-making with patients and caregivers, using structured tools to help people understand what they are choosing. The authors acknowledge that some patients, particularly those who place high value on even small potential delays in disease progression, may decide the risks and costs are worth it. But they also note that deferring treatment while waiting for more evidence is a reasonable choice. The approval, in other words, does not settle the question of whether any individual should take the drug. It simply makes it possible to ask the question—and to do so with eyes open to both the promise and the peril.
Notable Quotes
Clinical benefits are modest at best, with uncertain impacts on quality of life, independence, and caregiver burden— Dr. Sharon Straus, geriatrician at Unity Health Toronto
The decision to initiate lecanemab should be individualized. Some patients may choose to proceed and accept the risks, while in some cases deferring treatment pending further evidence may be reasonable— Dr. Sharon Straus and coauthors in the Canadian Medical Association Journal
The Hearth Conversation Another angle on the story
Why did Canada approve a drug that the experts themselves describe as having modest benefits?
Because it's the first drug that actually slows cognitive decline in early Alzheimer's, even if only slightly. In a disease where we've had almost nothing, something is powerful—even if that something is imperfect.
But if the benefits are modest and the risks include brain swelling and bleeding, why would anyone take it?
Some people will. They're watching their memory slip away and they want to fight back, even if the fight is uncertain. For them, a small delay in decline is worth the monitoring and the risk.
What about the cost? Thirty-five to forty thousand dollars a year is not trivial.
It's not. And because most provinces haven't committed to covering it, patients are paying out of pocket. That means access depends on wealth, not just on medical need.
So this is really a story about inequality in healthcare?
It's a story about what happens when a new treatment arrives before we fully understand it, and before we've decided as a society how to pay for it. The drug itself is just the beginning of the conversation.
What would change your mind about recommending it?
More evidence about whether it actually improves how people live—not just whether it slows amyloid buildup. And a decision from provinces about whether they'll fund it. Right now, patients are making this choice in a vacuum.